Ed prostate cancer, but until recently,
its anti-cancer effects have not been tested in women. Inhibition of heat shock protein Hsp a chaperone protein, which is expressed in breast cancer far. It stabilizes oncogenic proteins Customers and tr gt Survive a tumor cell. In a pr Clinical trial Caldas Lopes and colleagues have shown PLX-4720 that Hsp inhibitor PU HTI xenograft growth in vivo gel TNBC Deleted, shows both partial tumor regression and completely’s Full response. In vitro inhibition of Hsp has been shown that low regulating members of the MAPK pathway Ras and Raf-phase dependent GM tumor proliferation remove-Dependent hsp degrade act and Bcl XL activated apoptosis and inhibits the activation of NF KB, Akt, ERK, Tyk and PKC whereby the Invasivit t TNBC.
The results suggest that Hsp may be a target for effective therapy and pluripotent triple negative. Clinical trials in TNBC Management Options chemotherapy until recently due to the absence of a specific target were systemic Behandlungsm opportunities for TNBC cytotoxic chemotherapy is limited. TNBC phenotypes compared with other Ph Itself a more favorable outcome after chemotherapy have. Raf Inhibitors Shorter disease-free intervals and OS were observed in patients who have not re-watched U adjuvant chemotherapy. Zus Tzlich TNBC patients are known to have a h Here rate of pathological completely’s Full response compared to patients without TNBC have. But chemoresponsiveness lead to a better overall survival Found the NSABP trial B and B, which has involved a combination of neoadjuvant and adjuvant systems of doxorubicin and cyclophosphamide with or without docetaxel for patients who achieved PCR h Here DFS and OS compared with patients who continued not.
However, there are so-called triple-negative paradox: W can TNBC while more chemosensitive, the poor prognosis associated with the disease, k can by the high relapse rate in patients who do not achieve explained PCR rt. Numerous studies that have the timing of chemotherapy in the treatment of breast cancer showed that neoadjuvant therapy corresponds adjuvant disease-free survival and OS. A meta-analysis of nine randomized trials by Mauri et al, however, found that increased neoadjuvant therapy with FITTINGS risk of lokoregion Ren Fdbk cases In patients treated without surgery with radiotherapy was associated.
Since this meta-analysis was not a subset of TNBC patients, further studies on the issue of neoadjuvant therapy compared to adjuvant TNBC patients is warranted. The exact time of chemotherapy in the treatment of TNBC dense dose or metronomic planning is important and has been shown to not only survive progression-free improved, but pCR to erh Hen, k Nnte Turn mean more big s OS, the w weekly or zweiw weekly AC and paclitaxel benefit k can TNBC patients. Intensification of the dose may also improve event-free survival and overall survival in patients with multiple positive lymph nodes TNBC. Although studies, significant Erh Increase of DFS and OS demonstrated with neoadjuvant chemotherapy, there is a clinical benefit, given the availability of tissues and the F Ability to correlate potential biomarkers of disease response. Further experimental